Ticker

Analyst Price Targets — REX

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
August 26, 2024 4:05 pmJordan LevyTruist Financial$60.00$47.50StreetInsider REX American Resources (REX) PT Lowered to $60 at Truist Securities
May 30, 2024 7:08 amJordan LevyTruist Financial$65.00$51.09StreetInsider REX American Resources (REX) PT Lowered to $65 at Truist Securities
April 12, 2024 6:17 amJordan LevyTruist Financial$70.00$57.12StreetInsider REX American Resources (REX) PT Raised to $70 at Truist Securities

Latest News for REX

Betting on the Backbone: REX Files for AI Chipmaking ETF

Investor demand for AI chip manufacturers has surged this year. The industry is expected to reach revenues of $1.3 trillion in 2026, according to Yahoo Finance, driven by a global AI infrastructure buildout and a bottleneck for AI semiconductors and hardware.

ETF Trends • Jul 15, 2026
T-REX Launches T-REX 2X Long SKHY Daily Target ETF (NYSE Arca: HYNX)

MIAMI--(BUSINESS WIRE)--REX Shares ("REX") and Tuttle Capital Management ("TCM") today announce the launch of the T-REX 2X Long SKHY Daily Target ETF (NYSE Arca: HYNX), a leveraged ETF providing 2x daily long exposure to the SK hynix American Depositary Receipts (ADRs) (SKHY). HYNX is available in pre-market trading beginning at 4:00 a.m. ET. HYNX is designed to deliver 200% of the daily performance of the SK hynix…

Business Wire • Jul 14, 2026
REX Drone ETF Sees Inflows as Defense Spending Climbs

According to ETF Database, the REX Drone ETF (DRNZ) fund attracted approximately $11.28 million in inflows during the first week of the month. An additional $4.6 million arrived on July 7, bringing its five-day net inflows to $15.88 million.

ETF Trends • Jul 9, 2026
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for REX-8756, an oral, potent and selective STAT6 inhibitor, is being presented at two upcoming scientific congresses. At the European Association of Allergy and Clinical Immunology (EAACI) Congress…

GlobeNewsWire • Jun 12, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for REX.

No House trades found for REX.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top